EyePoint, Inc. - 8-K Filing
EyePoint reports Q3 2026 net loss of $95.6 million and announces strategic pivot to DME program following failed wet AMD Phase 3 trials. (Items: 2.02 Results of Operations and Financial Condition, 9.01 Financial Statements and Exhibits)